1. Organic anion transporter family: current knowledge;Anzai;J. Pharmacol. Sci.,2006
2. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin;Bhagunde;Br. J. Clin. Pharmacol.,2020
3. Drug transport by organic anion transporters (OATs);Burckhardt;Pharmacol. Ther.,2012
4. CDER, 2020. In vitro drug interaction studies - cytochrome p450 enzyme - and transporter-mediated drug interactions: guidance for industry. https://www.fda.gov/media/134582/download.
5. CDER, 2020. Clinical drug interaction studies - cytochrome P450 enzyme- and transporter-mediated drug interactions: guidance for industry. https://www.fda.gov/media/134581/download.